Northwest Biotherapeutics Statistics
Northwest Biotherapeutics (NBYB) Stock Statistics & Valuation Metrics
Total Valuation
Northwest Biotherapeutics has a market cap or net worth of EUR 256.39M. The enterprise value is EUR 374.52T.
- Market Cap
- EUR 256.39M
- Enterprise Value
- EUR 374.52T
Share Statistics
Northwest Biotherapeutics has 1,705,638,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,705,638,000
- Owned by Insiders
- ―
- Owned by Institutions
- 0.04%
Financial Efficiency
Northwest Biotherapeutics’s return on equity (ROE) is 1.29 and return on invested capital (ROIC) is -186.49%.
- Return on Equity (ROE)
- 1.29
- Return on Assets (ROA)
- -0.76
- Return on Invested Capital (ROIC)
- -186.49%
- Return on Capital Employed (ROCE)
- 5.76
- Revenue Per Employee
- 13.12K
- Profits Per Employee
- -585.50K
- Employee Count
- 105
- Asset Turnover
- 0.02
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Northwest Biotherapeutics is -6.79. Northwest Biotherapeutics’s PEG ratio is -0.07.
- PE Ratio
- -6.79
- PS Ratio
- 132.18
- PB Ratio
- -7.95
- Price to FCF
- -5.94
- Price to Operating Cash Flow
- -5.72
- PEG Ratio
- -0.07
Income Statement
In the last 12 months, Northwest Biotherapeutics had revenue of 1.38M and earned -61.48M in profits. Earnings per share was -0.04.
- Revenue
- 1.38M
- Gross Profit
- -959.00K
- Operating Income
- -59.91M
- Pretax Income
- -60.70M
- Net Income
- -61.48M
- EBITDA
- -49.67M
- Earnings Per Share (EPS)
- -0.04
Cash Flow
In the last 12 months, operating cash flow was -48.34M and capital expenditures 0, giving a free cash flow of -48.34M billion.
- Operating Cash Flow
- -48.34M
- Free Cash Flow
- -48.34M
- Free Cash Flow per Share
- -0.03
Dividends & Yields
Northwest Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -17.00%
- Earnings Yield
- -13.78%
Stock Price Statistics
- Beta
- 0.93
- 52-Week Price Change
- -41.18%
- 50-Day Moving Average
- 0.14
- 200-Day Moving Average
- 0.17
- Relative Strength Index (RSI)
- 50.18
- Average Volume (3m)
- 24.42K
Financial Position
Northwest Biotherapeutics as a current ratio of 0.06, with Debt / Equity ratio of -136.28%
- Current Ratio
- 0.06
- Quick Ratio
- 0.06
- Debt to Market Cap
- 0.18
- Net Debt to EBITDA
- -1.24
- Interest Coverage Ratio
- 6.89
Taxes
In the past 12 months, Northwest Biotherapeutics has paid 778.00K in taxes.
- Income Tax
- 778.00K
- Effective Tax Rate
- -0.01
Enterprise Valuation
Northwest Biotherapeutics EV to EBITDA ratio is -5.91, with an EV/FCF ratio of -7.04.
- EV to Sales
- 156.55
- EV to EBITDA
- -5.91
- EV to Free Cash Flow
- -7.04
- EV to Operating Cash Flow
- -7.04
Balance Sheet
Northwest Biotherapeutics has EUR 595.00K in cash and marketable securities with EUR 56.44M in debt, giving a net cash position of -EUR 55.85M billion.
- Cash & Marketable Securities
- EUR 595.00K
- Total Debt
- EUR 56.44M
- Net Cash
- -EUR 55.85M
- Net Cash Per Share
- -EUR 0.03
- Tangible Book Value Per Share
- -EUR 0.05
Margins
Gross margin is -39.02%, with operating margin of -2316.11%, and net profit margin of -1736.36%.
- Gross Margin
- -39.02%
- Operating Margin
- -2316.11%
- Pretax Margin
- -1776.30%
- Net Profit Margin
- -1736.36%
- EBITDA Margin
- -2648.37%
- EBIT Margin
- -2352.78%
Analyst Forecast
The average price target for Northwest Biotherapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 84.01%
- EPS Growth Forecast
- 62.78%
Scores
- Smart Score
- 4
- AI Score
- ―
